{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:29:29Z","timestamp":1740104969849,"version":"3.37.3"},"reference-count":5,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,4,5]],"date-time":"2014-04-05T00:00:00Z","timestamp":1396656000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"crossref","award":["RO1 HS0189960"],"award-info":[{"award-number":["RO1 HS0189960"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1002\/pds.3577","type":"journal-article","created":{"date-parts":[[2014,4,5]],"date-time":"2014-04-05T06:22:20Z","timestamp":1396678940000},"page":"440-441","source":"Crossref","is-referenced-by-count":0,"title":["Reply letter: are FDA prescription drug safety plans working? A case study of isotretinoin"],"prefix":"10.1002","volume":"23","author":[{"given":"Kevin","family":"Fain","sequence":"first","affiliation":[{"name":"Department of Epidemiology Johns Hopkins Bloomberg School of Public Health  Baltimore MD USA"},{"name":"Center for Drug Safety and Effectiveness Johns Hopkins University  Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Epidemiology Johns Hopkins Bloomberg School of Public Health  Baltimore MD USA"},{"name":"Center for Drug Safety and Effectiveness Johns Hopkins University  Baltimore MD USA"},{"name":"Division of General Internal Medicine, Department of Medicine Johns Hopkins Medicine  Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,5]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507133330206"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.819"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3481"},{"key":"e_1_2_4_5_1","unstructured":"FDABriefing Document for August 1 2007Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Members and Consultants. Available at:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007\u20104311b1\u201001\u2010fda.pdf(accessed December 13 2013)."},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1457"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3577","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3577","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:03:25Z","timestamp":1696338205000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1002\/pds.3577"],"URL":"https:\/\/doi.org\/10.1002\/pds.3577","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}